Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of unusually large options trading on Wednesday. Traders bought 1,002 put options on the company. This is an increase of 1,791% compared to the typical volume of 53 put options.

Maravai LifeSciences Price Performance

MRVI opened at $8.51 on Friday. The company has a current ratio of 11.32, a quick ratio of 10.47 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $2.14 billion, a P/E ratio of -8.60 and a beta of 0.02. The stock has a 50-day moving average price of $8.42 and a 200-day moving average price of $7.79. Maravai LifeSciences has a 12-month low of $4.52 and a 12-month high of $12.10.

Maravai LifeSciences (NASDAQ:MRVI) last released its earnings results on Wednesday, May 8th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.05). Maravai LifeSciences had a negative return on equity of 4.28% and a negative net margin of 47.81%. The firm had revenue of $64.18 million during the quarter, compared to the consensus estimate of $60.84 million. Equities analysts predict that Maravai LifeSciences will post -0.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on MRVI shares. Robert W. Baird boosted their price target on shares of Maravai LifeSciences from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Thursday, May 9th. Craig Hallum assumed coverage on Maravai LifeSciences in a report on Wednesday, April 10th. They issued a “buy” rating and a $15.00 price target on the stock. Finally, The Goldman Sachs Group cut their price objective on Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday, July 9th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $11.44.

Insider Transactions at Maravai LifeSciences

In related news, Director Gtcr Investment Xi Llc sold 9,940,974 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $9.81, for a total transaction of $97,520,954.94. Following the sale, the director now directly owns 20,150,005 shares in the company, valued at approximately $197,671,549.05. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

A number of institutional investors have recently made changes to their positions in MRVI. Wellington Management Group LLP raised its position in Maravai LifeSciences by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 70,658 shares of the company’s stock worth $707,000 after purchasing an additional 1,779 shares during the period. QRG Capital Management Inc. grew its stake in shares of Maravai LifeSciences by 11.7% during the first quarter. QRG Capital Management Inc. now owns 17,143 shares of the company’s stock valued at $149,000 after buying an additional 1,796 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Maravai LifeSciences by 310.2% in the second quarter. GAMMA Investing LLC now owns 3,585 shares of the company’s stock worth $26,000 after buying an additional 2,711 shares during the period. M&T Bank Corp boosted its holdings in Maravai LifeSciences by 17.3% during the 4th quarter. M&T Bank Corp now owns 20,107 shares of the company’s stock valued at $131,000 after acquiring an additional 2,972 shares during the period. Finally, Performa Ltd US LLC boosted its holdings in Maravai LifeSciences by 112.4% during the 4th quarter. Performa Ltd US LLC now owns 6,000 shares of the company’s stock valued at $39,000 after acquiring an additional 3,175 shares during the period. Hedge funds and other institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.